NCT04681001

Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers

Completed NA Last updated 25 August 2022

What this trial tests

NA trial testing nasal spray in Respiratory Viral Infection in 300 participants. Completed in 30 August 2021.

Timeline

20 December 2020

Primary endpoint
20 August 2021

30 August 2021

Quick facts

Lead sponsor	Marinomed Biotech AG
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	300
Start date	20 December 2020
Primary completion	20 August 2021
Estimated completion	30 August 2021
Sites	2 locations across Austria

Drugs / interventions tested

• nasal spray

Conditions studied

• Respiratory Viral Infection — all drugs for Respiratory Viral Infection →
• Common Cold — all drugs for Common Cold →
• Severe Acute Respiratory Syndrome (SARS) Pneumonia — all drugs for Severe Acute Respiratory Syndrome (SARS) Pneumonia →
• COVID-19 — all drugs for COVID-19 →

Sponsor

Marinomed Biotech AG — full company profile →

Who can join

Adults 18 to 70, any sex, with Respiratory Viral Infection or Common Cold. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, randomized placebo-controlled double blinded clinical trial in frontline healthcare workers managing COVID-19 patients. Participants will be weekly tested for SARS-CoV-2 and a panel of respiratory viruses. Treatment will be 3times a day for 84 days one puff into each nostirl and 3 puffs into mouth. Daily a symptom score will be recorded. The primary objective of the trial is to demonstrate that prophylactic treatment of health care workers managing COVID-19 patients with iota-carrageenan reduces symptoms of SARS-CoV-2 infections as well as infections with other respiratory viruses when compared to a placebo-treated control group.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. Carbohydrate-based drugs launched during 2000<i>-</i>2021.
   Cao X, Du X, Jiao H, An Q, et al · · 2022 · cited 126× · PMID 36213536 · DOI 10.1016/j.apsb.2022.05.020
2. Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease.
   Figueroa JM, Lombardo ME, Dogliotti A, Flynn LP, et al · · 2021 · cited 55× · PMID 34629893 · DOI 10.2147/ijgm.s328486
3. Therapeutics for COVID-19 and post COVID-19 complications: An update.
   Basu D, Chavda VP, Mehta AA. · · 2022 · cited 44× · PMID 35136858 · DOI 10.1016/j.crphar.2022.100086
4. Antiviral Strategies Using Natural Source-Derived Sulfated Polysaccharides in the Light of the COVID-19 Pandemic and Major Human Pathogenic Viruses.
   Ray B, Ali I, Jana S, Mukherjee S, et al · · 2021 · cited 38× · PMID 35062238 · DOI 10.3390/v14010035
5. 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update.
   Huang Z, Chavda VP, Vora LK, Gajjar N, et al · · 2022 · cited 29× · PMID 35496298 · DOI 10.3389/fphar.2022.899633
6. The antiviral activity of iota-, kappa-, and lambda-carrageenan against COVID-19: A critical review.
   Frediansyah A. · · 2021 · cited 29× · PMID 34222718 · DOI 10.1016/j.cegh.2021.100826
7. The Potential of Dietary Bioactive Compounds against SARS-CoV-2 and COVID-19-Induced Endothelial Dysfunction.
   Losso JN. · · 2022 · cited 9× · PMID 35268723 · DOI 10.3390/molecules27051623